Add to Favorites Newsroom RSS Share
fb-shareCardiovascular Research Foundation (CRF)
New York, NY USA

Our News on Newswise

Newswise: TAVI20_Social-Media-02-Twitter.png

PCR and TCT Announce the Creation of a New Educational Program: Partners in Learning

PCR and TCT are proud to announce the creation of a new educational program: “Partners in Learning.” The first of its kind will focus on TAVI practitioners, taking place on 21-22 March 2020 in Sao Paulo, Brazil. It is the first ever stand-alone...
21-Jan-2020 10:35 AM EST Add to Favorites

New Self-expanding TAVR Prosthesis Does Not Meet Non-Inferiority Compared to SAPIEN 3

The first randomized trial to compare the safety and efficacy of the new ACURATE neo transcatheter heart valve with the SAPIEN 3 TAVR device did not meet non-inferiority in patients with severe aortic stenosis.
30-Sep-2019 4:00 AM EDT Add to Favorites

New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis

The Portico IDE study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was...
30-Sep-2019 4:00 AM EDT Add to Favorites

Three-Year COAPT Data Demonstrates Continued Safety and Effectiveness in Patients with Heart Failure and Secondary Mitral Regurgitation

The three-year results from the COAPT trial demonstrated that reducing severe secondary mitral regurgitation (SMR) with the MitraClip device safely improves prognosis in selected heart failure (HF) patients. In addition, those patients that crossed...
30-Sep-2019 4:00 AM EDT Add to Favorites

New Five-Year Data Shows Similar Outcomes for TAVR and SAVR in Patients with Severe Aortic Stenosis and Intermediate Surgical Risk

Five-year results from the PARTNER 2A trial found that patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to...
30-Sep-2019 4:00 AM EDT Add to Favorites

New Data Show that Patients with Left Main Disease Treated with PCI or CABG Have Similar Composite Outcomes at Five Years

Patients with left main coronary artery disease (LMCAD) typically have a poor prognosis due to the large amount of myocardium at risk. Revascularization with either percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery...
30-Sep-2019 4:00 AM EDT Add to Favorites

Newswise: SaitoPhoto.jpg

TCT 2019 Master Operator Award to Be Presented to Shigeru Saito, MD

The Geoffrey O. Hartzler Master Operator Award will be presented to Shigeru Saito, MD, in a ceremony on September 27, 2019 at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research...
27-Sep-2019 2:05 PM EDT Add to Favorites

Shortened Three-month DAPT Duration After PCI Demonstrates Low Rate of Adverse Events in High-Bleeding Risk Patients

Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not increase myocardial infarction (MI) or stent thrombosis (ST) in high bleeding risk (HBR) patients treated with a contemporary...
26-Sep-2019 9:05 PM EDT Add to Favorites

see all news

Our Experts on Newswise

CRF to Hold Free Seminar on Living with Heart Failure for Patients and Caregivers

CRF will hold a free seminar, “Broken Hearts: Living with Heart Failure,” on Tuesday, June 6, 2017 for heart failure patients and caregivers at NewYork-Presbyterian Hospital. The seminar will focus on providing both patients and caregivers a...
9-May-2017 12:05 PM EDT

see all experts

Our YouTube Videos

Youtube feed not yet configured. Is this your Newswise member page? Contact to configure this module.


The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease.

CRF works to identify, develop and promote the latest advancements in the treatment of heart and vascular disease. By covering all aspects of the research continuum, we’re able to accelerate the speed with which breakthrough therapies reach patients through doctors, improving survival rates and quality of life for patients worldwide.

CRF carries out its mission by pursuing three basic goals:

The CRF Skirball Center for Innovation guides early ideas and innovations through comprehensive preclinical research programs to introduce practical clinical therapies to patients.

The CRF Clinical Trials Center plans and executes clinical investigations from first-in-man studies to large, multicenter, international trials and provides expert, independent qualitative and quantitative analyses of clinical and imaging data.

The CRF Center for Education trains practitioners in advanced techniques and innovations at more than 50 educational meetings and conferences each year, including the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

CRF is a 501(c)3 nonprofit organization.


Irma Damhuis
Director, External Relations


Judy Romero
Associate Director, External Relations


David Harrison
Harrison Communications


Twitter twitter-icon

Chat now!